Tests longer blood-cleaning sessions in people with kidney failure on dialysis
Compares 2-hour and 4-hour hemoadsorption with dialysis in adults with end-stage kidney disease.
Plain-language title generated from the registry record
Registry title: Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 who have been on stable hemodialysis for at least 3 months. It compares 2 hours and 4 hours of hemoadsorption added to dialysis.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- End-stage kidney disease on stable maintenance hemodialysis for at least 3 months, 3 times per week, each session at least 4 hours.
- Earlier treatment
- Stable hemodialysis for at least 3 months with a fairly fixed dialysis plan. Single-pool Kt/V of 1.2 or higher within the 8 weeks before enrollment.
- Biomarker or test result
- Single-pool Kt/V (spKt/V) of 1.2 or higher within 8 weeks before enrollment.
Main reasons for not taking part
- Life expectancy less than 1 year
- White blood cell count below 4 × 10⁹/L and/or platelet count below 60 × 10⁹/L
- Active or chronic bleeding in the gut, or a diagnosed clotting disorder
- Active cancer or active infection
- Pregnant or breastfeeding
This trial only enrols participants on dialysis. The registry sentence this rests on: Stable maintenance hemodialysis for ≥3 months, with a relatively fixed dialysis regimen
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07111260, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07111260
- Record updated
- 8 August 2025
- Original description
This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.Read full original descriptionShow less
Comparison of the Efficacy of Hemoadsorption Combined With Hemodialysis of Different Treatment Durations in Clearing Protein-Bound Uremic Toxins: A Randomized Crossover Controlled Trial
This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.
Inclusion: Age between 18 and 75 years, regardless of gender; Stable maintenance hemodialysis for ≥3 months, with a relatively fixed dialysis regimen; Receiving hemodialysis 3 times per week, each session lasting ≥4 hours; Single-pool Kt/V (spKt/V) ≥1.2 within 8 weeks prior to enrollment; Willing and able to sign the informed consent form.
Exclusion: Active or chronic gastrointestinal bleeding, or diagnosed coagulation disorders; Active malignant tumor; Active infection; White blood cell count < 4 × 10⁹/L and/or platelet count < 60 × 10⁹/L; Life expectancy less than 1 year; Pregnant or breastfeeding; Participation in another clinical trial within the past month or currently enrolled in one; Deemed unsuitable for the study by the investigator.